Company
SK Biopharmaceuticals Co. Ltd
Headquarters: Seongnam-si, South Korea
CEO: Mr. Jeong Woo Cho Ph.D.
Market Cap
₩7.338 Trillion
KRW as of July 1, 2025
US$5.41 Billion
SK Biopharmaceuticals Co. Ltd Categories
South Korea Healthcare BiotechnologySouth Korea Healthcare South Korea Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | ₩578.00 B |
| EBITDA | ₩226.70 B |
| Gross Profit TTM | ₩536.35 B |
| Profit Margin | 43.46% |
| Operating Margin | 17.78% |
| Quarterly Revenue Growth | 26.70% |
Stocks & Indices
SK Biopharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: KRX: 326030 wb_incandescent